 MIAMI, Aug. 30, 2021 GLOBE NEWSWIRE -- OPKO Health, Inc. NASDAQ: OPK announces the completion of enrollment in its Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19. The U.S. trial, A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of R AYALDEE calcifediol E xtended-relea s e C aps u l e s to Treat Symptomatic Patients Infected with SARS-CoV-2 REsCue , was expected to enroll approximately 160 subjects, including some with stage 3 or 4 chronic kidney disease CKD who are at higher risk for developing more severe illness. Final enrollment reached 171 subjects and topline data are expected later this year. 